Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
184
184 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- UtidelonePhase 38 trials
Beijing Biostar Pharmaceuticals Co., Ltd. · Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma
- JSKN003Phase 37 trials
Shanghai JMT-Bio Inc. · HER2-positive Colorectal Cancer, Advanced Solid Tumor, HER2-positive Gastric Cancer
- KN026PlacboPhase 37 trials
Shanghai JMT-Bio Inc. · HER2-positive Gastric Cancer, Advanced Breast Cancer, Resectable HER2-positive Breast Cancer
- OleclumabMEDI9447Phase 37 trials
AstraZeneca · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Metastatic Microsatellite-stable Colorectal Cancer
- LHRH AgonistPhase 36 trials
Roche (Genentech) · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, Early Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- tinengotinibTT-00420Phase 36 trials
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- HRS-6209Phase 35 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Breast Cancer, Advanced Unresectable or Metastatic Breast Cancer of Adults
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- PyrotinibPhase 35 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Solid Tumors, Non-small Cell Lung Cancer, HER2-expressing Advanced Solid Tumors
- AL8326Phase 34 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- DP303cPhase 34 trials
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · HER2-positive Breast Cancer, Advanced Solid Tumors, Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
- HLX22Phase 34 trials
Shanghai Henlius Biotech · HER2 + Breast Cancer, HER2-low Hormone Receptor Positive Breast Cancer, Gastroesophageal-junction Cancer
- JSKN016Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
- KL-A167Phase 34 trials
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Recurrent or Metastatic
- LasofoxifeneAZU-101Phase 34 trials
Sermonix Pharmaceuticals Inc. · Metastatic Breast Cancer, Vulvo Vaginal Atrophy (VVA), Locally Advanced or Metastatic Breast Cancer
- SPH4336Phase 34 trials
Shanghai Pharmaceuticals Holding Co., Ltd · Locally Advanced or Metastatic Breast Cancer, Breast Cancer Brain Metastases, Advanced Solid Tumors
- TQB2930Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer
- TQB3616Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- BEBT-209KCBI-0191Phase 33 trials
BeBetter Med Inc · HR+/HER2- Locally Advanced, Metastatic Breast Cancer, Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer
- ESG401Phase 33 trials
Qilu Pharmaceutical Co., Ltd. · Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC), Neoplasms, Breast
- IBI354Phase 33 trials
Innovent Biologics (Suzhou) Co. Ltd. · Locally Advanced Unresectable or Metastatic Solid Tumors, Ovarian, Primary Peritoneal
- LHRHLuteinizing hormone-releasing hormone agonist, Luteinizing Hormone-Releasing Hormone AgonistsPhase 33 trials
AstraZeneca · ER-Positive HER2-Negative Breast Cancer, Ovarian Cancer
- NSC 613327Phase 33 trials
BeBetter Med Inc · Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer, Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- TaxanePhase 33 trials
AstraZeneca · Breast Cancer; HER2-positive; Metastatic, Solid Tumors, Platinum-resistant Ovarian Cancer
- TersolisibLY4064809, STX-478Phase 33 trials
Eli Lilly · Breast Neoplasms, Neoplasm Metastasis, Breast Cancer
- A166Phase 32 trials
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Her 2 Positive Breast Cancer, HER2-positive Breast Cancer
- CDK4Phase 32 trials
Qilu Pharmaceutical Co., Ltd. · Advanced ER+/HER2- Breast Cancer, Breast Cancer
- CTXPhase 32 trials
Ascentage Pharma Group Inc. · CLL/SLL, Breast Cancer
- HLX87Phase 32 trials
Shanghai Henlius Biotech · HER2 + Breast Cancer
- JS105Phase 32 trials
Risen (Suzhou) Pharma Tech Co., Ltd. · Advanced Solid Tumors, Breast Cancer
- NuvastaticPhase 32 trials
Natureceuticals Sdn Bhd · Fatigue, Colon Cancer, Breast Neoplasms
- Nuvastatic 300Phase 32 trials
Natureceuticals Sdn Bhd · Fatigue Related to Cancer Treatment, Colon Cancer, Breast Cancer
- OBI-821OBI-833Phase 32 trials
OBI Pharma, Inc · Triple Negative Breast Cancer, Non-small Cell Lung Cancer
- of Physician's ChoicePhase 32 trials
BriaCell Therapeutics Corporation · Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.